Tyra Biosciences, Inc.
TYRA
$36.22
$0.220.61%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 23.66% | 35.09% | 35.45% | 39.05% | 38.43% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.41% | 25.87% | 27.45% | 29.34% | 30.34% |
| Operating Income | -27.41% | -25.87% | -27.45% | -29.34% | -30.34% |
| Income Before Tax | -38.70% | -33.37% | -30.86% | -27.82% | -25.09% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -38.70% | -33.37% | -30.86% | -27.82% | -25.09% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -38.70% | -33.37% | -30.86% | -27.82% | -25.09% |
| EBIT | -27.41% | -25.87% | -27.45% | -29.34% | -30.34% |
| EBITDA | -27.52% | -25.92% | -27.45% | -29.31% | -30.27% |
| EPS Basic | -33.44% | -17.01% | -5.63% | 3.00% | 6.72% |
| Normalized Basic EPS | -33.45% | -17.02% | -5.63% | 3.02% | 6.73% |
| EPS Diluted | -33.44% | -17.01% | -5.63% | 3.00% | 6.72% |
| Normalized Diluted EPS | -33.45% | -17.02% | -5.63% | 3.02% | 6.73% |
| Average Basic Shares Outstanding | 4.18% | 11.70% | 20.38% | 30.60% | 33.96% |
| Average Diluted Shares Outstanding | 4.18% | 11.70% | 20.38% | 30.60% | 33.96% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |